{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T05:42:20Z","timestamp":1759815740733,"version":"3.44.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.annder.2021.03.001","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T17:40:53Z","timestamp":1615570853000},"page":"69-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dermatology and COVID-19: Much knowledge to date but still a lot to discover"],"prefix":"10.1016","volume":"148","author":[{"given":"L.","family":"Le Cleach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2021.03.001_bib0075","unstructured":"Centre of Evidence Based Dermatology. CEBD Coronavirus Dermatology Resource. https:\/\/www.nottingham.ac.uk\/research\/groups\/cebd\/resources\/Coronavirusresource\/Coronavirushome.aspx access on February 18th 2021."},{"key":"10.1016\/j.annder.2021.03.001_bib0080","doi-asserted-by":"crossref","first-page":"e686","DOI":"10.1111\/jdv.16775","article-title":"Cutaneous manifestations in SARS-CoV-2 infection (COVID-19): a French experience and a systematic review of the literature","volume":"34","author":"Matar","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2021.03.001_bib0085","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/bjd.19163","article-title":"Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases","volume":"183","author":"Galv\u00e1n Casas","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2021.03.001_bib0090","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jaad.2020.06.1016","article-title":"The spectrum of COVID-19-associated dermatologic manifestations: an international registry of 716 patients from 31 countries","volume":"83","author":"Freeman","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2021.03.001_bib0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.annder.2020.12.002","article-title":"Cutaneous manifestations of COVID-19 in Franche-Comt\u00e9 (France): a monocentric study","author":"Jacquin-Porretaz","year":"2021","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2021.03.001_bib0100","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/bjd.19377","article-title":"Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on polymerase chain reaction and serology testing","volume":"183","author":"Le Cleach","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2021.03.001_bib0105","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/jamadermatol.2020.4324","article-title":"Clinical, laboratory, and interferon-alpha response characteristics of patients with chilblain-like lesions during the COVID-19 pandemic","volume":"157","author":"Hubiche","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2021.03.001_bib0110","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/jamadermatol.2020.4655","article-title":"Emerging evidence of the direct association between COVID-19 and chilblains\u00a0\u2013\u00a0Reply","volume":"157","author":"Baeck","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2021.03.001_bib0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.annder.2020.11.005","article-title":"Acute acral eruptions in children during the COVID-19 pandemic: characteristics of 103 children and their family clusters","author":"Hubiche","year":"2021","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2021.03.001_bib0120","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaci.2020.10.007","article-title":"Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study","volume":"147","author":"Mahil","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.annder.2021.03.001_bib0125","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-219498","article-title":"Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry","author":"Strangfeld","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annder.2021.03.001_bib0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.annder.2020.12.001","article-title":"Topical steroids and topical tacrolimus appear safe regarding the COVID-19 epidemic","author":"Souaid","year":"2021","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2021.03.001_bib0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.annder.2021.01.005","article-title":"Impact of the COVID-19 pandemic on children with psoriasis","author":"Beytout","year":"2021","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2021.03.001_bib0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.annder.2021.01.004","article-title":"Psychological and professional impact of COVID-19 lockdown on French dermatologists: data from a large survey","author":"Misery","year":"2021","journal-title":"Ann Dermatol Venereol"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963821000302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963821000302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:10:34Z","timestamp":1758971434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963821000302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0151963821000302"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2021.03.001","relation":{},"ISSN":["0151-9638"],"issn-type":[{"type":"print","value":"0151-9638"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dermatology and COVID-19: Much knowledge to date but still a lot to discover","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2021.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}